tag:www.gov.uk,2005:/drug-safety-updateDrug Safety Update about Radiology and imaging2023-01-25T13:24:51+00:00HM Governmenttag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-december-20222023-01-25T13:24:51+00:00Letters and medicine recalls sent to healthcare professionals in December 2022A summary of recent letters and notifications sent to healthcare professionals about medicines.
tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-march-20222022-04-19T14:27:17+01:00Letters and medicine recalls sent to healthcare professionals in March 2022A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices. Includes a recent recall of Accuretic (quinapril hydrochloride and hydrochlorothiazide).tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-december-20212022-01-18T13:18:06+00:00Letters and medicine recalls sent to healthcare professionals in December 2021A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-november-20212021-12-10T11:00:52+00:00Letters and medicine recalls sent to healthcare professionals in November 2021A summary of recent letters, medicine recalls and notifications sent to healthcare professionals.tag:www.gov.uk,2005:/drug-safety-update/letters-and-medicine-recalls-sent-to-healthcare-professionals-in-march-20212021-04-27T14:22:10+01:00Letters and medicine recalls sent to healthcare professionals in March 2021A summary of letters and recent medicine recalls and notifications sent to healthcare professionals.tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-april-20202020-05-21T14:45:31+01:00Letters and drug alerts sent to healthcare professionals in April 2020A summary of letters and drug alerts recently sent to healthcare professionals.tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-february-20202020-03-18T14:23:59+00:00Letters and drug alerts sent to healthcare professionals in February 2020 Letters were sent on Typhim Vi vaccines, Mepact (mifamurtide), and Xeljanz (tofacitinib) and an alert issued to recall Emerade 150 microgram adrenaline pens. tag:www.gov.uk,2005:/drug-safety-update/letters-and-drug-alerts-sent-to-healthcare-professionals-in-june-20192019-07-17T13:34:54+01:00Letters and drug alerts sent to healthcare professionals in June 2019Letters were sent about Myocrisin (sodium aurothiomalate), Cerliponase alfa (Brineura�), Darzalex�(daratumumab), retinoids�, and febuxostat (Adenuric). A recall alert was issued for medicines that were taken out of the regul�tag:www.gov.uk,2005:/drug-safety-update/medical-device-alerts-issued-in-march-20192019-04-16T15:53:15+01:00Medical Device Alerts issued in March 2019Alerts were issued about Pagewriter Cardiographs and Efficia Monitors and Fresenius 5008 & 5008S haemodialysis machines.
tag:www.gov.uk,2005:/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects2019-03-21T11:50:07+00:00Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects Disabling, long-lasting or potentially irreversible adverse reactions affecting musculoskeletal and nervous systems have been reported very rarely with fluoroquinolone antibiotics. Fluoroquinolone treatment should be discont�tag:www.gov.uk,2005:/drug-safety-update/medicines-taken-during-pregnancy-please-report-suspected-adverse-drug-reactions-including-in-the-baby-or-child-on-a-yellow-card2018-07-17T14:35:39+01:00Medicines taken during pregnancy: please report suspected adverse drug reactions, including in the baby or child, on a Yellow CardReport to the Yellow Card Scheme suspected adverse reactions associated with medicines taken during pregnancy experienced by women or the baby or child. Obstetricians and midwives have a particularly important role in provid�tag:www.gov.uk,2005:/drug-safety-update/letters-sent-to-healthcare-professionals-in-may-20182018-06-22T12:47:55+01:00Letters sent to healthcare professionals in May 2018Letters were sent about azithromycin, Lynparza�(Olaparib), Xgeva� (denosumab), Lymphoseek (tilmanocept), ReoPro (abciximab) and dolutegravir; you still have time to complete a quick survey to tell us your views on the way me�tag:www.gov.uk,2005:/drug-safety-update/gadolinium-containing-contrast-agents-omniscan-and-iv-magnevist-no-longer-authorised-multihance-and-primovist-for-use-only-in-liver-imaging2018-02-06T16:59:33+00:00Gadolinium-containing contrast agents: Omniscan and iv Magnevist no longer authorised, MultiHance and Primovist for use only in liver imagingOmniscan and intravenous Magnevist are now no longer authorised for use and a product recall of any existing unexpired stock is underway.tag:www.gov.uk,2005:/drug-safety-update/gadolinium-containing-contrast-agents-removal-of-omniscan-and-iv-magnevist-restrictions-to-the-use-of-other-linear-agents2017-12-14T15:31:36+00:00Gadolinium-containing contrast agents: removal of Omniscan and iv Magnevist, restrictions to the use of other linear agents A review has found that low levels of gadolinium can be retained in the brain and other tissues after administration of gadolinium-containing contrast agents (GdCAs). There is currently no evidence that gadolinium deposition�tag:www.gov.uk,2005:/drug-safety-update/hyoscine-butylbromide-buscopan-injection-risk-of-serious-adverse-effects-in-patients-with-underlying-cardiac-disease2017-02-20T13:16:59+00:00Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac diseasePrescribing information has been updated to help to minimise the risk of serious adverse reactions in patients with cardiac disease.tag:www.gov.uk,2005:/drug-safety-update/cobicistat-ritonavir-and-coadminsitration-with-a-steroid-risk-of-systemic-corticosteroid-adverse-effects2016-12-14T11:28:40+00:00Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects Coadministration of a corticosteroid with an HIV-treatment-boosting agent may increase the risk of adrenal suppression due to a pharmacokinetic interaction. tag:www.gov.uk,2005:/drug-safety-update/letters-sent-to-healthcare-professionals-in-march-20162016-04-18T13:42:57+01:00Letters sent to healthcare professionals in March 2016In March 2016, letters were sent regarding SGLT2 inhibitors, insulin lispro, natalizumab, noradrenaline, radium-223 dichloride, aflibercept and idelalisib.tag:www.gov.uk,2005:/drug-safety-update/vemurafenib-zelboraf-risk-of-potentiation-of-radiation-toxicity2015-11-12T10:14:53+00:00Vemurafenib (Zelboraf�): risk of potentiation of radiation toxicity Prescribers should be aware of the risk of potentiation of radiation toxicity with vemurafenib when given before, during, or after radiotherapytag:www.gov.uk,2005:/drug-safety-update/letters-sent-to-healthcare-professionals-in-october-20152015-11-12T10:09:25+00:00Letters sent to healthcare professionals in October 2015In October 2015, letters were sent to healthcare professionals to provide safety information for the anticancer medicines crizotinib and vemurafenibtag:www.gov.uk,2005:/drug-safety-update/letters-sent-to-healthcare-professionals-in-march-20152015-04-29T11:52:55+01:00Letters sent to healthcare professionals in March 2015Last month, letters were sent regarding ketoconazole HRA and radium-223 dichloride (Xofigo).tag:www.gov.uk,2005:/drug-safety-update/letters-sent-to-healthcare-professionals-since-november-20142015-02-16T15:32:29+00:00Letters sent to healthcare professionals since November 2014Since November 2014, letters were sent regarding vismodegib (Erivedge �), chlorhexidine solutions, carbocisteine oral liquid (Mucodyne Paediatric 125mg/5ml), regadenoson (Rapiscan), a parenteral nutrition emulsion (Triomel),�tag:www.gov.uk,2005:/drug-safety-update/metoclopramide-risk-of-neurological-adverse-effects2014-12-11T14:35:34+00:00Metoclopramide: risk of neurological adverse effectsRestricted dose and duration of use.tag:www.gov.uk,2005:/drug-safety-update/blue-dyes-risk-of-serious-allergic-reactions2014-12-11T14:32:40+00:00Blue dyes: risk of serious allergic reactionsSurgeons reminded to have competent personnel and emergency facilities available for at least 1 hour after administration of the blue dye.tag:www.gov.uk,2005:/drug-safety-update/gadolinium-containing-contrast-agents-new-advice-to-minimise-the-risk-of-nephrogenic-systemic-fibrosis2014-12-11T14:28:17+00:00Gadolinium-containing contrast agents: new advice to minimise the risk of nephrogenic systemic fibrosisGadolinium-containing contrast agents are associated with a varying degree of risk of nephrogenic systemic fibrosis. See advice below to minimise risk in the following vulnerable groups: patients with renal impairment; patie�tag:www.gov.uk,2005:/drug-safety-update/ecoflac-infusion-solutions-risk-of-air-embolism2014-12-11T14:24:01+00:00Ecoflac infusion solutions: risk of air embolismTo avoid the risk of air embolism, these products should not be infused under pressure.